iQSTEL Seeks Stockholder Approval for Highly Dilutive Financing and Executive Equity Overhaul

summarizeSummary

iQSTEL seeks stockholder approval to exceed Nasdaq's 19.99% issuance cap for its $50M equity line and a newly detailed ADI Funding true-up that could massively dilute existing holders, while also overhauling executive equity compensation with convertible preferred stock.

check_boxKey Events · Corporate Governance and Compliance · IQST

• Stockholder Approval Sought to Exceed 19.99% Cap

  The company seeks approval to issue shares beyond the 19.99% Nasdaq exchange cap under its $50M M2B equity line and ADI Funding Series D conversions, including ratification of any prior excess issuances.

• ADI Funding True-Up Mechanism Revealed

  The Series D Preferred Stock held by ADI Funding carries a true-up adjustment with a maximum ratio of 5, applied retroactively, meaning the company may have already issued or will issue a massive number of additional shares at deeply discounted prices.

• Executive Equity Compensation Overhauled

  CEO and CFO common stock grants are being replaced with Series B Preferred Stock (convertible to 12.5 common shares each, with a 24% annual dividend), and FY-2025 grants of 20,000 and 14,000 Series B shares respectively are proposed, subject to stockholder approval.

• Dilution Risk Amplified by Financial Distress

  The company already faces going-concern doubts and negative working capital; these financing and compensation moves could severely dilute existing common stockholders while enriching insiders and funding partners.

auto_awesomeAnalysis · IQST · Technology

iQSTEL is asking stockholders to greenlight two major actions that could dramatically dilute existing holders. First, approval to issue shares beyond the 19.99% Nasdaq cap under its $50M equity line with M2B Funding and under a previously undisclosed true-up mechanism for ADI Funding's Series D Preferred Stock. The ADI true-up, with a maximum ratio of 5 applied retroactively, means the company may have already issued—or will issue—a massive number of shares at deeply discounted prices, potentially wiping out significant value for current stockholders. Second, the company wants to replace CEO and CFO common stock grants with Series B Preferred Stock, which converts to 12.5 common shares each and carries a 24% annual dividend, further diluting common holders. These moves come as the company already faces going-concern doubts and negative working capital, raising serious concerns about the cost and desperation of this financing.